Our data identify a novel chondroitin sulfate-based control mechanism for a Wnt/beta-catenin-Collagen pro-metastatic axis, and provide evidence for a potential therapeutic use of CS-E treatment as an inhibitor of Wnt/beta-catenin signaling in breast and other cancers. The gene discussed is CTNNB1; the disease is cancer.